HMGA2 Promotes Intestinal Tumorigenesis by Facilitating MDM2‐mediated Ubiquitination and Degradation of P53

Yuhong Wang,Lin Hu,Jian Wang,Xiangwei Li,Sana Sahengbieke,Jingjing Wu,Maode Lai

DOI: https://doi.org/10.1002/path.5164

2018-01-01

Abstract:High mobility group A2 (HMGA2) is an architectural transcription factor that promotes human colorectal cancer (CRC) aggressiveness by modulating the transcription of target genes. The degradation of p53 is mediated by murine double minute 2 (MDM2) in a proteasome‐dependent manner. Here we report that HMGA2 promotes cell cycle progression and inhibits apoptosis in CRC cells in vitro. We also developed an intestinal epithelial cell‐specific Hmga2 knock‐in (KI) mouse model. It revealed that the Hmga2 KI promoted chemical carcinogen‐induced tumorigenesis in the intestine in vivo. In studying the underlying molecular mechanism, we found that HMGA2 formed a protein complex with p53. The tetramerization domain of p53 (amino acids 294–393) and the three AT‐hook domains (amino acids 1–83) of HMGA2 were responsible for their direct interaction. We also found that HMGA2 directly bound to MDM2 and the central acidic and zinc finger domains of MDM2 (amino acids 111–360) were required for interaction with HMGA2. Furthermore, our results indicated that HMGA2 promoted MDM2‐mediated p53 ubiquitination and degradation. Interestingly, Hmga2 overexpression in Hmga2 KI mice resulted in an increase in the accumulation of ubiquitinated p53. In addition, in two large CRC cohorts, it was demonstrated that high HMGA2 expression was predictive of an adverse outcome in the p53‐negative subgroup of CRC patients. In summary, our data have established for the first time a novel mechanism by which HMGA2 functions with p53 and MDM2 to promote CRC progression. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.